



Ain Shams University  
Faculty of Medicine  
Department of Anesthesiology,  
Intensive Care and Pain Management

# **Perioperative management of patient undergoing bariatric surgery**

**An Essay**

Submitted for Partial Fulfillment of Master Degree in Anesthesia

***By***

**Mohamed Fathy Fathy**  
M.B., B. Ch.- Ain Shams University

Under Supervision of

**Prof. Mervat Mohamed Marzouk**

Professor of Anesthesiology, Intensive Care and pain management  
Faculty of Medicine – Ain Shams University

**Dr. Khaled Mostafa Khalaf**

Lecturer of Anesthesiology, Intensive Care and pain management  
Faculty of Medicine – Ain Shams University

**Dr. Wael Abd Al Moneim Mohamed**

Lecturer of Anesthesiology, Intensive Care and pain management  
Faculty of Medicine – Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2016**



## ***Acknowledgement***

*First of all, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.*

*Really I can hardly find the words to express my gratitude to **Prof. Mervat Mohamed Marzouk**, Professor of Anesthesiology, Intensive Care and pain management, Faculty of Medicine – Ain Shams University, for her supervision, continuous help, encouragement throughout this work and tremendous effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.*

*I would like also to express my sincere appreciation and gratitude to **Dr. Khaled Mostafa Khalaf**, Lecturer of Anesthesiology, Intensive Care and pain management, Faculty of Medicine – Ain Shams University, for his continuous directions and support throughout the whole work.*

*I cannot forget the great help of **Dr. Wael Abd Al Moneim Mohamed**, Lecturer of Anesthesiology, Intensive Care and pain management, Faculty of Medicine – Ain Shams University for his invaluable efforts, tireless guidance and for his patience and support to get this work into light.*

*Words fail to express my love, respect and appreciation to **my wife** for her unlimited help and support.*

*Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.*



**Mohamed Fathy Fathy**

# Contents

	Page
Acknowledgement .....	--
List of Abbreviations.....	i
List of Tables .....	iii
List of Figures .....	iv
Introduction .....	1
Aim of essay .....	3
<b>Chapter (1):</b>	
Pathophysiological changes in obese patient.....	4
<b>Chapter (2):</b>	
Preoperative assessment of obese patient .....	35
<b>Chapter (3):</b>	
Intraoperative management of obese patient .....	42
<b>Chapter (4):</b>	
Types of bariatric surgery .....	55
<b>Chapter (5):</b>	
Post operative management .....	64
Summary. ....	78
References. ....	80
Summary in Arabic. ....	--

## List of Abbreviations

AaDO <sub>2</sub>	: Alveolar-arterial oxygen partial pressure
AF	: Atrial fibrillation
AHI	: Apnea hypopnea index
AI	: Apnea index
AV	: Abdominal visceral fat
BMI	: Body mass index
BP	: Blood pressure
BV	: Blood volume
CAD	: Coronary artery disease
CHD	: Coronary heart disease
CHF	: Congestive heart failure
CO	: Cardiac output
CPAP	: Continuous positive airway pressure
DO <sub>2</sub>	: Oxygen delivery
ERV	: Expiratory reserve volume
FEV <sub>1</sub>	: Forced expiratory volume in first second
FFA	: Free fatty acid
FFM	: Fat free mass
FRC	: Functional residual capacity
HI	: Hypopnea index
IBW	: Ideal body weight
IL-6	: Interleukin 6
IR	: Insulin resistance
LAGB	: Laparoscopic adjustable gastric banding
LBW	: Lean body weight
LVEF	: Left ventricular ejection fraction
LVH	: Left ventricular hypertrophy
LVM	: Left ventricular mass
MO	: Morbid obese

## **List of Abbreviations** (Cont.)

MVO <sub>2</sub>	:	Myocardial oxygen consumption
NASH	:	Non alcoholic steato-hepatitis
NDNMBS	:	Non depolarizing neuromuscular blockers
NO	:	Nitric oxide
NREM	:	Non rapid eye movement
OHS	:	Obesity hypoventilation syndrome
OSA	:	Obstructive sleep apnea
OS-MRS	:	Obesity surgery mortality risk score
PACU	:	Post anaesthetic care unit
PE	:	Pulmonary embolism
PH	:	Pulmonary hypertension
PONV	:	Postoperative nausea and vomiting
PSG	:	Polysmnography
REM	:	Rapid eye movement
RYGB	:	Roux en Y gastric bypass
SaO <sub>2</sub>	:	Oxygen saturation
SV	:	Stroke volume
T2D	:	Type 2 diabetes
TBV	:	Total blood volume
TBW	:	Total body weight
TLC	:	Total lung capacity
TNF	:	Tumor necrosis factor
TOF	:	Train of four
VO <sub>2</sub>	:	Global oxygen consumption
VTE	:	Venous thromboembolism

## List of Figures

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
(1)	Ramp position in morbid obese patient.	49
(2)	Laparoscopic adjustable gastric banding operation.	56
(3)	Sleeve gastrectomy operation.	58
(4)	Roux en Y gastric bypass operation.	59
(5)	Biliopancreatic diversion with duodenal switch operation.	61

## List of Tables

Table	Title	Page
(1)	ECG changes in morbid obese patients	15
(2)	Calculation of weight formula in obese patients	46
(3)	Dosing scalar of common anaesthetic drugs	47
(4)	Percentage of weight loss within first year according to type of surgery	63

# Introduction

Obesity classified as a major health problem with a mild to severe health implications which include an increased risk for coronary artery disease, hypertension, dyslipidemia, diabetes mellitus, gall bladder disease, degenerative joint disease, sleep disorders, socioeconomic and psychosocial impairment (**Tank and Gohil, 2011**).

Implication for anaesthetic and perioperative care of severely obese patients are various, induction of anaesthesia is associated with potential risks as difficult airway, pulmonary aspiration of gastric contents, periods of hypoxia and hypercapnia, perioperatively may increase pulmonary vascular resistance and precipitate acute right sided heart failure especially in patients with pre-existing cardiac disease (**Brodsky *et al.*, 2001**).

The limited information available concerning pharmacodynamics and pharmacokinetics of perioperatively administered medications in severe obesity make a challenge to proper drug dosing in those patients and to manage those patients intraoperative with their pre-existing diseases and to control and avoid complications postoperatively especially with co-morbidities in those patients (**Ertatad, 2003**).

Bariatric surgery provides significant and sustained weight loss option for morbidly obese patients which improves the quality of the life, surgeries are classified into



many categories as example: gastric banding, gastric bypass, gastroplasty that can be done open or laparoscopic (**Buchwald and Buchwald, 2003**).

## **Aim of The Essay**

The aim of this essay is to highlighten the perioperative anaesthetic management of bariatric surgery patient and to anticipate and avoid postoperative complications.

## Pathophysiology

Obesity is described as an elevated level of fat storage in the form of hypertrophy and or hyperplasia of fat cells, known as adipocytes. Given the complexities of body composition analysis, the body mass index act as a surrogate for the amount of fat in the body.

Body mass index is defined as the body weight in kg divided by the square of the body height in meters, Obesity has been defined as BMI more than  $30 \text{ kg/m}^2$ , and more than  $35 \text{ kg/m}^2$  obesity related comorbidity and more than  $40 \text{ kg/m}^2$  is called morbid obesity.

The obesity is associated with cardiovascular deterioration, which include excess abdominal visceral fat (AVF), atherogenic, dyslipidemia, hypertension, insulin resistance, hyperglycemia, and a pro-thrombotic and pro-inflammatory state. Abdominal visceral fat should be considered a paracrine organ because it secretes hormones and inflammatory bio-active peptides, collectively known as adipokines (adipocytokines) (**Despres *et al.*, 2008**).

At ideal BMI adipokines have purely beneficial effects on metabolism, cardiac function and vascular endothelial well-being. However, as AVF increases in volume, excessive amounts of these hormones and inflammatory adipokines have detrimental effects on a variety of organ systems, including the heart and circulation Independent of hypertension, obstructive sleep apnea (OSA), coronary artery disease, and type 2

diabetes, excess AVF causes metabolic and structural changes of the heart and peripheral circulation, Hemodynamically this “cardio-metabolic” syndrome in its early stages is characterized by increased blood volume (BV), stroke volume (SV), cardiac output (CO), and preserved indices of global systolic pump performance, the most recognized being left ventricular ejection fraction (LVEF). The primary causes of obesity cardiomyopathy are myocardial fibrosis, fatty infiltration of the myocardium and the inappropriate accumulation of free fatty acids (FFA) and neutral lipids within the cardiomyocytes, Through the process of lipotoxicity, lipid overload causes cellular dysfunction, cell death, and ultimately clinically relevant cardiac dysfunction, If untreated, this eventually results in congestive heart failure and premature death (**Peeters et al., 2003**).

### **Adipokines:**

Traditionally, adipose tissue has been perceived as an inert organ whose sole function is as a repository for storing excess energy in the form of triglycerides, It is now known that AVF secretes hormones beneficial to metabolic well-being, namely leptin, adiponectin, and the inflammatory adipokines (**Hajer et al., 2008**).

#### **1. Leptin:**

In lean individuals, leptin is known to act on the satiety area of the hypothalamus to modulate and suppress appetite. Increased leptin levels have a direct effect on blood pressure (BP), cardiac remodeling, myocyte contraction, and may be a

cause of left ventricular hypertrophy (LVH), insulin resistance, hyperinsulinemia, hyperglycemia and diabetic dyslipidemia (**Perego *et al.*, 2005**).

## 2. Adiponectin:

Is an adipocyte-produced hormone that is totally cardioprotective which improves insulin sensitivity, decreases non-esterified fatty acid uptake, and reduces gluconeogenesis. In skeletal muscle, adiponectin stimulates both glucose and fatty acid use and antiatherosclerotic effects and protects against endothelial dysfunction by increasing local nitric oxide (NO) production, protects cells from inflammation that result from high glucose levels or tumor necrosis factor alpha (TNF- $\alpha$ ), while it also inhibits plaque initiation, progression, rupture and thrombosis (**Harmancy *et al.*, 2008**).

## 3. Inflammatory adipokines:

Inflammation, which is normally mediated by inflammatory adipokines, is a protective response of tissue that eliminates noxious agents and debris, and is closely tied to tissue repair, however, inflammatory adipokines, through enhanced synthesis of substances such as the potent vasoconstrictor endothelin-1, are responsible for decreased production or availability of NO. This results in small vessel disease, including endothelial dysfunction with attendant dysregulation of vascular tone and vasomotor function (**Zhang, 2008**).

#### **4. Angiotensinogen:**

Angiotensinogen, a precursor of angiotensin II, is mainly produced in the liver, but with increasing levels of obesity, angiotensinogen is produced in excess by visceral adipocytes. Excessive production of angiotensin II provides one of several etiologies causing obesity-induced pressure-overload hypertension with attendant LVH, as well as direct toxicity to cardiac myocytes and vascular endothelium (Zhang, 2008).

#### **5. Plasminogen activator inhibitor-1:**

Reduces fibrinolytic activity and induces a pro-thrombotic, hypercoagulable state, predisposes to platelet aggregation and adhesion, clot formation, venous thrombosis and pulmonary thromboembolism (Hajer *et al.*, 2008).

#### **6. Resistin:**

Alters cardiac contractility and induces cardiomyocyte hypertrophy and depresses cell contractility, as well as contraction and relaxation velocity.

#### **7. Tumor necrosis factor- $\alpha$ :**

Appear early in the metabolic syndrome and correlate highly with insulin resistance. Which decrease the produced NO, which leads to coronary artery and peripheral vascular endothelial dysfunction (Hajer *et al.*, 2008).

## 8. Interleukin-6:

Elevated levels of IL-6 predict the development of type 2 diabetes and myocardial infarction. Increased IL-6 levels are directly correlated with increased plasma FFAs and may also decrease insulin sensitivity by depressing adiponectin secretion.

### Pathophysiological changes in cardiovascular system:

#### **Global oxygen consumption[VO<sub>2</sub>]:**

Progressive increases in AVF, and especially fat-free mass (FFM) elicit an increased demand for metabolic oxygen. At rest, total body oxygen consumption in the obese and MO exceeds that of individual of ideal BMI. Maintenance or augmentation of CO, hemoglobin concentration and arterial blood oxygen saturation (SaO<sub>2</sub>) in the peri-operative period is important in order to optimize oxygen delivery (DO<sub>2</sub>). Optimization of DO<sub>2</sub> to meet VO<sub>2</sub> prevents anaerobic metabolism, the consequences of which are metabolic acidosis and depression of myocardial contractility. If CO fails to increase with physiologic stress, such as in severe anemia and/or hypovolemia, oxygen transport becomes inadequate, leading to anerobic metabolism with lactic acidosis (Seres *et al.*, 2003).

#### **Blood volume:**

Total blood volume (TBV) progressively increases over the full range of BMI, , The increase in plasma volume,